Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + tenofovir
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Entecavir + tenofovir is a fixed-dose combination of two oral antiviral agents used primarily for the treatment of chronic hepatitis B virus (HBV) infection, especially in patients with previous nucleoside/nucleotide analogue treatment failure or multidrug-resistant HBV. Entecavir is a guanosine nucleoside analogue that inhibits HBV DNA polymerase, thereby blocking viral replication. Tenofovir is an adenosine nucleotide analogue that also inhibits viral reverse transcriptase and DNA polymerase, causing chain termination and inhibition of viral synthesis. The combination leverages their high genetic barriers to resistance and non-overlapping resistance profiles to provide effective suppression of HBV replication in patients with complex resistance mutations. This regimen has demonstrated efficacy and safety as rescue therapy for chronic hepatitis B, particularly in those with prior antiviral drug resistance[1][3][4][5].
- Brand names
- Baraclude + Viread
- Other names
- ETV-TDF combination
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + tenofovir.